Detalhe da pesquisa
1.
SMARCB1 Loss in Poorly Differentiated Chordomas Drives Tumor Progression.
Am J Pathol
; 193(4): 456-473, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36657718
2.
Gain-of-function genetic screen of the kinome reveals BRSK2 as an inhibitor of the NRF2 transcription factor.
J Cell Sci
; 133(14)2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32546533
3.
A conditional mouse expressing an activating mutation in NRF2 displays hyperplasia of the upper gastrointestinal tract and decreased white adipose tissue.
J Pathol
; 252(2): 125-137, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32619021
4.
High Frequency of Ovarian Cyst Development in Vhl2B/+;Snf5+/- Mice.
Am J Pathol
; 188(7): 1510-1516, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29684361
5.
The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
J Pathol
; 242(3): 371-383, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28444909
6.
Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
J Pathol
; 238(3): 389-400, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26356327
7.
SWI/SNF chromatin remodeling complexes and cancer.
Am J Med Genet C Semin Med Genet
; 166C(3): 350-66, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25169151
8.
ARID1A loss is associated with increased NRF2 signaling in human head and neck squamous cell carcinomas.
PLoS One
; 19(2): e0297741, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38358974
9.
NRF2 Activation in Trp53;p16-deficient Mice Drives Oral Squamous Cell Carcinoma.
Cancer Res Commun
; 4(2): 487-495, 2024 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38335300
10.
Establishment and characterization of MRT cell lines from genetically engineered mouse models and the influence of genetic background on their development.
Int J Cancer
; 132(12): 2767-77, 2013 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23197309
11.
Alanine supplementation exploits glutamine dependency induced by SMARCA4/2-loss.
Nat Commun
; 14(1): 2894, 2023 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37210563
12.
BRG1 co-localizes with DNA replication factors and is required for efficient replication fork progression.
Nucleic Acids Res
; 38(20): 6906-19, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20571081
13.
TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice.
Oncogene
; 41(25): 3423-3432, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35577980
14.
BRG1 mutations found in human cancer cell lines inactivate Rb-mediated cell-cycle arrest.
J Cell Physiol
; 226(8): 1989-97, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21520050
15.
A cytoskeletal function for PBRM1 reading methylated microtubules.
Sci Adv
; 7(14)2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33811077
16.
Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma.
Mol Cancer Res
; 18(12): 1777-1788, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32855269
17.
Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines.
Clin Cancer Res
; 26(15): 3908-3917, 2020 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32156746
18.
Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism.
Elife
; 92020 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33355532
19.
Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type.
Clin Cancer Res
; 26(16): 4402-4413, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32409304
20.
Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5(+/-);p53(+/-) mice.
Mol Carcinog
; 48(12): 1139-48, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19676100